Author

Kumar Prabhash

Observed names: K Prabhash, Prabhash, Kumar

Institutions: Homi Bhabha National Institute, Tata Memorial Hospital, Advanced Centre for Treatment, Research and Education in Cancer

Observed institutions: Homi Bhabha National Institute, Tata Memorial Hospital, Advanced Centre for Treatment, Research and Education in Cancer

ORCID: 0000-0003-4182-3735

Observed ORCID: 0000-0003-4182-3735

OpenAlex ID: A5111830268

Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference?

2013 · K Prabhash, VM Patil, et al. · Indian Journal of Cancer · 67

Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis

2013 · PS Pai, AD Vaidya, et al. · Indian Journal of Cancer · 57

Metronomic weekly paclitaxel in advanced unresectable esophageal cancer

2013 · V Noronha, V Patil, et al. · Indian Journal of Cancer · 15

Weekly cisplatin (30–40 mg/m 2 ) as radiosensitizer: Is it high or moderate emetic agent?

2016 · K Prabhash, A Karpe, et al. · Indian Journal of Cancer · 5

Referral pattern for neoadjuvant chemotherapy in the head and neck cancers in a tertiary care center

2014 · K Prabhash, VM Patil, et al. · Indian Journal of Cancer · 5

Recurrent sinonasal teratocarcinosarcoma with intracranial extension: Case report

2014 · K Prabhash, A Joshi, et al. · Indian Journal of Cancer · 5

Translating Innovation Into Practice: Dissemination of Immune Checkpoint Inhibitors and Their Toxicity Management Across the Globe

2026 · Mehak Trikha, Susan Dent, et al. · American Society of Clinical Oncology Educational Book · 1

Study protocol for a randomized, double-blind, placebo-controlled clinical trial to assess chemoprotective efficacy of Aqueous standardized extract of Tinospora cordifolia (AsSET) in patients receiving Docetaxel based chemotherapy for advanced / metastatic solid tumors

2026 · Priyanka Singh, Aditi Shirsat, et al. · medRxiv

Evidence for Dose Optimization of Immune Checkpoint Inhibitors

2026 · Sewanti Limaye, Vanita Noronha, et al. · Journal of Immunotherapy and Precision Oncology

Low-dose pembrolizumab with chemotherapy in advanced NSCLC: A phase 3 randomized trial.

2026 · Nandini Sharrel Menon, Vanita Noronha, et al. · Journal of Clinical Oncology

Effects of genome-wide modifiers of response to next-generation FGFR inhibitors in solid tumors—An Indian multicentric study.

2026 · Chirantan Bose, Vidya H. Veldore, et al. · Journal of Clinical Oncology

Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic NSCLC

2026 · Sree Siva Kumar Raja Addagalla, Vanita Noronha, et al. · ecancermedicalscience

Cancer caregiver support system: A pilot study to assess the effect of improved caregiver support on postoperative recovery of oral cancer patients

2026 · Meghna Kumar, Priya Kumari, et al. · Indian Journal of Cancer

Works count: 14

Citation count: 155

H-index: 5

I10-index: 3